BJMO - volume 13, issue 7, november 2019
A. Hébrant PhD, M. Lammens MD, PhD, C. Van den Broecke MD, N. D’Haene MD, PhD, J. Van den Oord MD, PhD, A. Vanderstichele MD, PhD, A. Dendooven MD, PhD, P. Neven MD, PhD, K. Punie MD, PhD, G. Floris MD, PhD, J. Van der Meulen PhD, HA. Poirel MD, PhD, C. Dooms MD, PhD, S. Rottey MD, PhD, T. Boterberg MD, PhD, L. Brochez MD, PhD, M.C. Burlacu MD, G. Costante MD, D. Creytens MD, PhD, P. De Paepe MD, PhD, R. De Pauwn MD, B. Decallonne MD, PhD, F. Dedeurwaerdere MD, H. Denys MD, PhD, L. Ferdinande MD, PhD, R. Forsyth MD, PhD, M. Garmyn MD, PhD, T. Gevaert MD, PhD, J. De Grève MD, PhD, E. Govaerts MD, E. Hauben MD, PhD, J. Kerger MD, PhD, O. Kholmanskikh Van Criekingen MD, PhD, V. Kruse MD, PhD, Y. Lalami MD, L. Lapeire MD, PhD, P. Lefesvre MD, PhD, J.P. Machiels MD, PhD, B. Maes MD, PhD, G. Martens MD, PhD, M. Remmelink MD, PhD, I. Salmon MD, PhD, R. Sciot MD, PhD, S. Tejpar MD, PhD, K. Van de Vijver MD, PhD, L. Van de Voorde MD, I. Van den Berghe MD, A. Van den Bruel MD, K. Vandecasteele MD, PhD, L. Vanwalleghem MD, K. Vermaelen MD, PhD, R. Salgado MD, PhD, E. Wauters MD, B. Weynand MD, PhD, E. Van Valckenborgh PhD, G. Raicevic PhD, M. Van den Bulcke PhD, P. Pauwels MD, PhD
In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their relevance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This methodology was applied on different solid tumours for which molecular testing is a clear clinical need.
(BELG J MED ONCOL 2019;13(7):286–95)
Read moreBJMO - volume 11, issue 1, february 2017
C. Quaghebeur MD, N. Whenham MD, J.P. Machiels MD, PhD, J-P. Haxhe MD, A-P. Schillings MD, E. Laterre MD, X. Catteau MD, R. Poncin MD, L. Duck MD, PhD
Breast phyllodes tumours account for less than 0.5% of breast tumours, their diagnosis is therefore often made after pathological exam. They are fibroepithelial lesions of the breast, and are classified as benign, borderline or malignant. For malignant phyllodes tumours, aggressive behaviour with risk of local and distant recurrence may be seen. Therefore, at least one centimetre free-margins, or mastectomy, should be preferred for local malignant tumours. No prospective randomised data exist to elucidate the role of adjuvant chemotherapy, but radiotherapy should probably be offered after breast conservative surgery for borderline and malignant tumours. For metastatic disease, there is no standard chemotherapy regimen. Doxorubicin is the main recommended drug, based on scarce data. Palliative surgery or radiotherapy may also be offered. We present here a patient with lung metastatic disease who partially responded to a platin-etoposide regimen after doxorubicin failure, and make a short review of the literature.
(BELG J MED ONCOL 2017;11(1):26–28)
Read moreBJMO - volume 11, issue 9, february 2017
E. Seront MD, PhD, J.P. Machiels MD, PhD
Immunotherapy harnesses the immune system to recognize and destroy cancer cells. This review focuses on the different agents that are currently approved in genitourinary cancers and highlights promising therapeutic strategies in this field. The clinical data generated in advanced urological cancer, advanced renal cell carcinoma (RCC) and metastatic prostate cancer will be discussed
Read moreBJMO - volume 9, issue 3, july 2015
S. Lejeune MD, J.P. Machiels MD, PhD
The human epidermal growth factor receptor family is composed of four tyrosine kinase receptors (HER-1 or EGFR, HER-2, HER-3 and HER-4). Human epidermal growth factor receptor pathways play a critical role in human cancer and are involved in tumour proliferation, apoptosis, angiogenesis, and cell migration/invasion. Pan-HER inhibitors such as afatinib, dacomitinib, and neratinib induce irreversible inhibition of all the dimers formed by the human epidermal growth factor receptor family. In clinical practice, only afatinib is approved by the Food and Drug Administration for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Today, those molecules are still in development and their activity and safety investigated in clinical trials. The most common adverse effects of the pan-HER inhibitors are diarrhoea and skin toxicity.
(BELG J MED ONCOL 2015;9(3):99–103)
Read more
Top
